Compare Johnson & Johnson (JNJ) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Johnson & Johnson trades at $249.42 (market cap $598.96B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.06. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| JNJ | VIG | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $239.13 |
52-Week Low | $164.36 | $204.09 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VIG trades at $235.95, down 0.7% on the day, with a neutral technical signal and bullish moving averages. The ETF focuses on dividend growth from financially healthy U.S. large-caps, offering a low 0.04% expense ratio. Recent news highlights its role in diversifying Magnificent Seven exposure and building passive income, with a dividend scheduled for June 2026.
Outlook remains stable for long-term investors seeking quality dividend growth, though competition from higher-yield ETFs presents a risk. The neutral technical stance suggests near-term consolidation, while fundamental strength in holdings supports steady appreciation. Market sentiment is positive amid focus on reliable income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
